Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tetrahydrobiopterin

Small molecule · developed by BioMarin Pharmaceutical

Phase 1 Most advanced trial
BMRN Developer
1 Registered trials

What is Tetrahydrobiopterin?

Tetrahydrobiopterin is a cofactor essential for the activity of aromatic amino acid hydroxylases. It supports phenylalanine degradation, neurotransmitter biosynthesis and nitric oxide production, and is studied in intermittent claudication and peripheral artery disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
sapropterin, kuvan
Drug type
Small molecule
Pathways
phenylalanine degradation, neurotransmitter biosynthesis, nitric oxide production
Therapy area
Cardiovascular
Developer
BioMarin Pharmaceutical (BMRN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04800692 Phase 1 Claudication, Intermittent Active not recruiting BMRN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Claudication, IntermittentPeripheral Artery DiseasePeripheral Vascular Diseases

More from BioMarin Pharmaceutical

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BMRN page.

Follow BMRN, the company behind Tetrahydrobiopterin

See BMRN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMRN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.